TY  - GEN
AU  - Bumgardner,G L
AU  - Hardie,I
AU  - Johnson,R W
AU  - Lin,A
AU  - Nashan,B
AU  - Pescovitz,M D
AU  - Ramos,E
AU  - Vincenti,F
TI  - Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation
SN  - 0041-1337
PY  - 2001///1011
KW  - Acute Disease
KW  - Adrenal Cortex Hormones
KW  - administration & dosage
KW  - Antibodies, Monoclonal
KW  - adverse effects
KW  - Antibodies, Monoclonal, Humanized
KW  - Azathioprine
KW  - Cyclosporine
KW  - Daclizumab
KW  - Graft Rejection
KW  - prevention & control
KW  - Graft Survival
KW  - Humans
KW  - Immunoglobulin G
KW  - Immunosuppressive Agents
KW  - Kidney Transplantation
KW  - Lymphoproliferative Disorders
KW  - etiology
KW  - Neoplasms
KW  - Receptors, Interleukin-2
KW  - antagonists & inhibitors
KW  - Survival Rate
KW  - Time Factors
N1  - Publication Type: Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1097/00007890-200109150-00017
ER  -